Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic testing is superior over endogenous pharmacometabolomic markers to predict safety of haloperidol in patients with alcohol-induced psychotic disorder.
Skryabin V, Zastrozhin M, Parkhomenko A, Lauschke VM, Smirnov V, Petukhov A, Pankratenko E, Pozdnyakov S, Koporov S, Denisenko N, Akmalova K, Bryun E, Sychev D. Skryabin V, et al. Among authors: sychev d. Curr Drug Metab. 2022 Dec 28. doi: 10.2174/1389200224666221228112643. Online ahead of print. Curr Drug Metab. 2022. PMID: 36579390
Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA, Zastrozhin MS, Miroshnichenko II, Baymeeva NV, Smirnov VV, Grishina EA, Ryzhikova KA, Mirzaev KB, Markov DD, Skryabin VY, Snalina NE, Nosikova PG, Savchenko LM, Bryun EA. Sychev DA, et al. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136. doi: 10.1515/dmpt-2017-0021. Drug Metab Pers Ther. 2017. PMID: 28787271
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS, Antonenko AP, Nesterenko EV, Seyfullaeva LI, Mustafina VR, Esakova AP, Grishina EA, Sorokin AS, Skryabin VY, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Drug Metab Pers Ther. 2018 Dec 19;33(4):187-194. doi: 10.1515/dmpt-2018-0019. Drug Metab Pers Ther. 2018. PMID: 30325732
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Zastrozhin MS, Sorokin AS, Agibalova TV, Grishina EA, Antonenko AР, Rozochkin IN, Duzhev DV, Skryabin VY, Galaktionova TE, Barna IV, Orlova AV, Aguzarov AD, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: sychev da. Hum Psychopharmacol. 2018 Nov;33(6):e2677. doi: 10.1002/hup.2677. Epub 2018 Oct 25. Hum Psychopharmacol. 2018. PMID: 30357930
How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Skryabin VY, Zastrozhin MS, Torrado MV, Grishina EA, Ryzhikova KA, Shipitsyn VV, Galaktionova TE, Sorokin AS, Bryun EA, Sychev DA. Skryabin VY, et al. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. doi: 10.1515/dmpt-2019-0026. Drug Metab Pers Ther. 2020. PMID: 32134726
192 results